Rapid Micro Biosystems (RPID) vs. Its Competitors Financial Comparison

Rapid Micro Biosystems (NASDAQ:RPIDGet Rating) is one of 43 publicly-traded companies in the “Analytical instruments” industry, but how does it weigh in compared to its rivals? We will compare Rapid Micro Biosystems to related companies based on the strength of its profitability, analyst recommendations, institutional ownership, valuation, risk, dividends and earnings.


This table compares Rapid Micro Biosystems and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Rapid Micro Biosystems -296.26% -44.23% -25.78%
Rapid Micro Biosystems Competitors -250.85% 6.38% -11.11%

Analyst Ratings

This is a summary of current ratings and recommmendations for Rapid Micro Biosystems and its rivals, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Rapid Micro Biosystems 0 1 3 0 2.75
Rapid Micro Biosystems Competitors 329 1348 1834 59 2.45

Rapid Micro Biosystems currently has a consensus target price of $22.67, suggesting a potential upside of 499.65%. As a group, “Analytical instruments” companies have a potential upside of 37.85%. Given Rapid Micro Biosystems’ stronger consensus rating and higher probable upside, equities analysts clearly believe Rapid Micro Biosystems is more favorable than its rivals.

Insider & Institutional Ownership

69.8% of Rapid Micro Biosystems shares are owned by institutional investors. Comparatively, 61.5% of shares of all “Analytical instruments” companies are owned by institutional investors. 38.0% of Rapid Micro Biosystems shares are owned by company insiders. Comparatively, 13.6% of shares of all “Analytical instruments” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares Rapid Micro Biosystems and its rivals gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Rapid Micro Biosystems $23.23 million -$73.52 million -0.17
Rapid Micro Biosystems Competitors $1.16 billion $344.59 million -25.66

Rapid Micro Biosystems’ rivals have higher revenue and earnings than Rapid Micro Biosystems. Rapid Micro Biosystems is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Rapid Micro Biosystems Company Profile (Get Rating)

Rapid Micro Biosystems, Inc., a life sciences technology company, provides products for the detection of microbial contamination in the manufacture of pharmaceutical, medical devices, and personal care products in North America, Europe, and Asia. The company offers Growth Direct platform, which includes Growth Direct system, proprietary consumables, lab information management system connection software, and comprehensive customer support and validation services. Its platform automates and modernizes the manual microbial quality control (MQC) testing workflows for therapeutic modalities, such as biologics, vaccines, cell and gene therapies, and sterile injectables. The company also provides installation and verification, technical training, and support services. Its solutions are used in environmental monitoring, water testing, bioburden, and sterility release testing applications. The company was formerly known as Genomic Profiling Systems, Inc. and changed its name to Rapid Micro Biosystems, Inc. in January 2007. Rapid Micro Biosystems, Inc. was incorporated in 2006 and is headquartered in Lowell, Massachusetts.

Receive News & Ratings for Rapid Micro Biosystems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rapid Micro Biosystems and related companies with MarketBeat.com's FREE daily email newsletter.